Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of escalating doses GX-I7 in combination with
standard dose pembrolizumab, and to evaluate objective response rate (ORR) in subjects with
refractory or relapsed TNBC